JHEP Reports

Article	Citations
Increased carbohydrate deficient transferrin: Whisky or candy?	194
Reply to: “Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans”	137
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?	126
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD	107
Copyright and information	78
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis	76
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice	67
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis	66
Predicting liver ablation volumes with real-time MRI thermometry	65
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st	62
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	62
A small animal model of chronic hepatitis E infection using immunocompromised rats	62
Time for a globally unified chronic HBV terminology?	56
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool	54
Emerging roles of circular RNAs in liver cancer	54
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”	51
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives	51
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]	48
Copyright and information	48
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis	47
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer	46
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging	46
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation	45
Comparative Effectiveness of Antidiabetic Therapies on Hepatic Decompensation in Patients with Type 2 Diabetes: A Target Trial Emulation	43
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis	43

HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	43
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort	42
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes	41
Statistical precision of p values: a note on “Liver fibrosis progression analyzed with AI predicts renal decline”	41
MELD 3.i: A Bayesian framework for updating the model for end-stage liver disease score	41
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data	41
Epigenetics of alcohol-related liver diseases	40
Editorial Board page	38
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication	38
Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment	37
Editorial Board page	37
Copyright and information	37
Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency	36
Contents	36
Understanding virologic heterogeneity in chronic hepatitis B treatment	35
A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium	35
p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis	35
Editorial Board page	35
Reply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”	35
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV	34
SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH	34
Arachidonic acid activates NLRP3 inflammasome in MDSCs via FATP2 to promote post-transplant tumour recurrence in steatotic liver grafts	34
PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle	33
Failure-to-Rescue as a Determinant of Overall Survival Following Resection for Perihilar Cholangiocarcinoma	32
Xanthine oxidase promotes hepatic lipid accumulation through high fat absorption by the small intestine	31
Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis	30
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study	30
Predicting the need for early TIPS in patients with cirrhosis and ascites: More art than science	30
Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice	30
Potential role of liver-resident CD3+ macrophages in HBV clearance in a mouse hepatitis B model	29
RAC1 as a novel therapeutic target for acute liver failure	29
Macrophage MRC2 Deficiency Mitigates HFD-Induced MASLD by Downregulating CD147-Regulated TNF-α Production Macrophage MRC2 Facilitates MASLD via the CD147-TNF-α Axis	29
Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis	29
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis	28
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey	28
Deep learning can predict cardiovascular events from liver imaging	28
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection	28
Monitoring of hepatitis E virus infection and replication by functional tagging of the ORF2 protein	27
Targeting fibrosis and steatohepatitis through the metabolism – results from the ESSENCE trial	27
Reply to: “Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma”	27
Corrigendum to: ‘Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia’ (JHEP Reports, Volume 6, Issue 7, July 2024, 101090)	27
Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology	26
Cholangiocarcinoma-on-a-chip: A human 3D platform for personalised medicine	26
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma	26
Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity	26
Dual-tracer PET/CT in the management of hepatocellular carcinoma	26
Contents	26
Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosis	25
“Development of a CRE/CREB-Driven HBx Responsive HBV Cell Culture Reporter System for Antiviral Drug Evaluation”	25
Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries	25

Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis	24
Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet	24
Disparities in transplant access and outcomes after first cirrhosis decompensation in alcohol-related liver disease	24
Editorial Board page	24
Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy	24
CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis	24
Non-invasive biomarkers of Fontan-associated liver disease	23
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆	23
Anatomical resection is associated with reduced early recurrences in HCC: A machine learning analysis	23
Regulatory T cell therapy in autoimmune liver disease and transplantation	23
Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy	23
Reply to: “Trans-splenic anterograde coil assisted transvenous obliteration vs. retrograde transvenous obliteration: Are we heading the right way?”	23
Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis	22
Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection	22
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation	22
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure	22
Editorial Board page	21
Corrigendum to ‘A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation’ [JHEP Reports 6	21
Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis	21
Does ammonia really disrupt brain oxygen homeostasis?	21
Diagnostic accuracy of transient elastography in MASLD is independent of MRI PDFF steatosis in a multicenter study	21
Application of a deep learning algorithm for the diagnosis of HCC	21
Small molecule drugs promote repopulation of transplanted hepatocytes by stimulating cell dedifferentiation	21
Serum proteomics of adults with acute liver failure provides mechanistic insights and attractive prognostic biomarkers	21
Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma	20
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab	20
Orphan drug Uttroside B Impedes NASH Progression and HCC Development in Experimental Models	20
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies	20
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma	20
Prevalence of Rocahepevirus ratti (rat hepatitis E virus) in humans and rats in China	20
Guideline-enhanced large language models outperform physician-test takers on EASL Campus quizzes multiple choice questions	20
Myeloid TGF-β signaling shapes liver macrophage heterogeneity and metabolic liver disease pathogenesis	20
ADIPOSE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY PROTECTS AGAINST HEPATIC STEATOSIS BY UPREGULATING PPARα ACTIVITY	19
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort	19
Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis	19
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors	19
Resolvin D1-mediated cellular crosstalk protects against MASH	19
Evolving epidemiology of HCC in Spain	18
QuickStroop for screening for minimal hepatic encephalopathy in patients with cirrhosis	18
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis	18
Acknowledging our reviewers	18
Copyright and information	18
Good long-term outcomes of primary sclerosing cholangitis in childhood	18
Should all pediatric patients with type 1 autoimmune hepatitis be screened for inflammatory bowel disease?	18
Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: Post hoc analysis of the PROSPER trial	18
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice	18
Copyright and information	17
High precision-cut liver slice model to study cell-autonomous antiviral defense of hepatocytes within their microenvironment	17
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis	17
The multi-omic basis for hepatic encephalopathy recurrence: Analysis of the THEMATIC Trial	17
Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis	17
Transcriptomics unveils immune metabolic disruption and a novel biomarker of mortality in patients with HBV-related acute-on-chronic liver failure	17
Innovative approaches to the management of ascites in cirrhosis	17
Challenges in the diagnosis and treatment of genetic cholestasis in adults	17
LAPTM4B enhances the stemness of CD133+ liver cancer stem-like cells via WNT/β-catenin signaling	17
Corrigendum to “Missed opportunities in HCV care: Trends in late diagnosis and treatment” [JHEP Reports 7 (2025) 101474]	17
Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis	17
DHCR7 inhibition ameliorates MetALD and HCC in mice and human 3D liver spheroids	17
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis	17
Thyroid dysfunction in MASLD: Results of a nationwide study	17
Editorial Board page	16
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis	16
Corrigendum to ‘Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation’ [JHEP Reports 6 (2024) 100983]	16
Circadian control of ConA-induced acute liver injury and inflammatory response via Bmal1 regulation of Junb	16
Editorial Board page	16
Single-cell analysis of mature hepatocytes reveals an IRF1-driven restriction of HDV infection	16
Contents	16
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison	16
Contents	16
Liver specification of human iPSC-derived endothelial cells transplanted into mouse liver	16
Distribution of non-ceruloplasmin-bound copper after i.v. 64Cu injection studied with PET/CT in patients with Wilson disease	15
Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis	15
Traditional lifestyle factors partly mediate the association of socioeconomic position with intrahepatic lipid content: The Maastricht study	15
Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease	15
Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation	15
Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort	15
Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer	15
Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1	15
Reply to: “Statins in MASLD: Challenges and future directions”	15
Dyrk2 gene transfer suppresses hepatocarcinogenesis by promoting the degradation of Myc and Hras	15

Genome-wide meta-analysis identifies nine loci associated with higher risk of hepatocellular carcinoma development	15
Contents	15
B4GALNT1 promotes hepatocellular carcinoma stemness and progression via integrin α2β1-mediated FAK and AKT activation	15
The ‘social gradient' in primary liver cancer in France: A national observational study	15
Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice	15
Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study	15
Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes	15
Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy	15
Erratum to ‘Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease’ (JHEP Reports 5 [2023] 100836)	15
Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease	14
New targets for NAFLD	14
Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component	14
AI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomes	14
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort	14
Immunomodulatory receptor VSIG4 is released during spontaneous bacterial peritonitis and predicts short-term mortality	14
Editorial Board page	14
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis	14
Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?	14
3D Endothelial cell scaffolds protect liver explants and exhibit therapeutic effects on liver fibrosis	14
Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease	14
Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma	14
ABCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome	14
A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications	14
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study	14
Characterisation of forkhead box protein A3 as a key transcription factor for hepatocyte regeneration	14
Contents	14
Endoscopic ultrasound-guided portosystemic pressure gradient measurement vs. transjugular balloon occlusion measurement in patients with cirrhosis (ENCOUNTER): A bicentric EU study	13
Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure	13
Contents	13
SBRT for bridging and downstaging HCC before transplant	13
Fructoholism in adults: The importance of personalised care in metabolic dysfunction-associated fatty liver disease	13
NTCP ubiquitination enables HBV infection	13
Transcriptomic landscapes of effective and failed liver regeneration in humans	13
Waiting time dictates impact of frailty: A Spanish multicenter prospective study	13
A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice	13
Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation	13
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD	13
Kinase suppressor of Ras 1 (KSR1) promotes liver carcinogenesis via activation of the RAS/RAF/MEK/ERK signaling pathway	13
Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging	13
Editorial Board page	13
GDF15 is associated with hepatocellular senescence and correlates with mortality in patients with alcohol-associated hepatitis	12
Rethinking risk indices in pediatric MASLD	12
Impact of bacterial infections prior to liver transplantation on post-transplant outcomes in patients with cirrhosis	12
Contents	12
Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)	12
Drug-induced liver injury in children: A nationwide cohort study from China	12
Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia	12
Risk of portal hypertensive complications preventable by TIPS in patients with ascites	12
Infection prevention and control programme and COVID-19 measures: Effects on hospital-acquired infections in patients with cirrhosis	12
Editorial Board page	12
Ketamine restriction correlates with reduced cholestatic liver injury and improved outcomes in critically ill patients with burn injury	12
Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival	12
Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome	12
Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)	12
Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts	12
Hepatic venous pressure gradient in sinusoidal obstruction syndrome: Diagnostic value and link with histological lesions	12
Reply to: “Ductular reaction is a prognostic factor in primary biliary cholangitis”	12
Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly	12
Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans	11
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study	11
Editorial Board page	11
Contents	11
Copyright and information	11
Downregulation of hepatic METTL3 contributes to APAP-induced liver injury in mice	11
Copyright and information	11
Contents	11
Copyright and information	11
Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease	11
Contents	11
Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease	11
LSECtin attenuates hepatic Th17 expansion in a murine model of cirrhosis and signals through the LAG-3 receptor	11
AI-derived body composition parameters as prognostic factors in patients with HCC undergoing TACE in a multicenter study	10
Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report	10
Implementing a new HCV model of care for people who use drugs	10
Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis	10
Ultra-selective Radiation Segmentectomy (uRS) for Early-Stage Hepatocellular Carcinoma (HCC)	10
AI-based tumor-infiltrating lymphocyte scoring system for assessing HCC prognosis in patients undergoing liver resection	10
Clinical burden of HDV in Spain: Incidence, prevalence, and associated comorbidities	10
Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis	10
Use of albumin infusion for cirrhosis-related complications: An international position statement	10
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases	10
A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation	10
C/EBPβ–VCAM1 axis in Kupffer cells promotes hepatic inflammation in MASLD	10
Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFNα non-response	10
Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts	10
Effect of plasma exchange with albumin replacement on albumin functionality and organ dysfunction in acute-on-chronic liver failure	10
Odevixibat in Progressive Familial Intrahepatic Cholestasis subtypes: insights from emerging real-world evidence	10
Preoperative TIPS prevents the development of postoperative acute-on-chronic liver failure in patients with high CLIF-C AD score	10
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination	10
A natural history study of paediatric non-alcoholic fatty liver disease over 10 years	9
24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARγ	9
Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies	9
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial	9
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab	9
Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis	9